AstraZeneca obesity pill yields 10.5% weight loss in trial

• Patients on the highest dose (75 mg) lost 11.8% of body weight after 36 weeks, with 89% achieving at least 5% weight loss; this trails Novo's Wegovy pill (14% loss) and Lilly's Foundayo (12% loss) in effectiveness
• Most common side effects were gastrointestinal, including nausea (55% vs 20% placebo), constipation (41% vs 6%), and vomiting (27% vs 5%), though discontinuation rates remained low
• AstraZeneca acquired elecoglipron from China's Eccogene for up to $2 billion in late 2023 and plans to explore combinations with other medicines for obesity-related conditions like diabetes and heart disease

AstraZeneca Obesity Pill Shows Promising Weight Loss Results in Mid-Stage Trial

Key Trial Results:

AstraZeneca announced that its experimental obesity pill, elecoglipron, achieved 10.5% weight loss in patients after 26 weeks in a mid-stage trial. At the highest dose (75mg), patients lost 11.8% of their body weight after the full 36-week trial duration. Nearly 89% of patients on the highest dose achieved at least 5% weight loss, meeting the trial's primary endpoints.

Company and Competitive Landscape:

AstraZeneca is positioning elecoglipron to compete in the rapidly growing obesity market dominated by Novo Nordisk and Eli Lilly. The company acquired the drug from China's Eccogene for approximately $2 billion in late 2023. Current competitors include:

• Novo Nordisk's Wegovy pill: ~14% weight loss
• Eli Lilly's Foundayo pill: 12% weight loss
• Roche's enicepatide injection: 22.7% weight loss after 48 weeks

Clinical Details:

The study enrolled 310 adults with obesity or overweight conditions. At the 50mg dose, patients lost 8-9% of body weight. Common side effects included gastrointestinal issues: nausea (55% vs. 20% placebo), constipation (41% vs. 6%), diarrhea (35% vs. 25%), and vomiting (27% vs. 5%). Despite these effects, discontinuation rates remained low.

Market Implications:

AstraZeneca plans to advance elecoglipron to late-stage trials and explore combination therapies for obesity-related conditions including diabetes, kidney disease, and heart disease. The once-daily pill format represents a cornerstone of the company's obesity strategy as it seeks to capture market share in this lucrative therapeutic area. A separate trial also showed positive results for blood sugar control in type 2 diabetes patients.